Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain
Go back to Heron Therapeutics Reports Positive Top-Line Results from Phase 2 Study of HTX-011 in the Management of Post-Operative Pain| HERON THERAPEUTICS (NASDAQ: HRTX) | Delayed: 0.43 +0.02 (4.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.41 | 52 Week High | $31.32 | |||
| Open | $0.41 | 52 Week Low | $13.95 | |||
| Day High | $0.43 | P/E | N/A | |||
| Day Low | $0.41 | EPS | $-3.29 | |||
| Volume | 6,425,231 | |||||
